EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieÄquivalenzstudieOpen Access · CC BY-NC-ND 4.0

Immunogenicity and Safety of a Purified Vero Rabies Vaccine—Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial

Andrea-Clemencia Pineda-Peña, Qian Jiang, Celine Petit, Joanna Korejwo-Peyramond, Yves Donazzolo, Mathilde Latreille, Marie-Claude Homery, Valerie Babin, Sonia Benamor, Sylvie Pichon, Françoise Guinet-Morlot, Ada-Maria Minutello

Clinical Infectious Diseases · 14.06.2024 · 78 (6) · 1748-1756

DOI: 10.1093/cid/ciae137 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 13.03.2024. Verfasst von Andrea-Clemencia Pineda-Peña und 11 weiteren Autor:innen. Beteiligte Einrichtung: Global Clinical Immunology, Sanofi, Campus Mérieux, Marcy l'Etoile, France. Hauptthemen laut MEDLINE: Rabies Vaccines, Rabies, Post-Exposure Prophylaxis, Antibodies, Viral. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A next-generation Vero cell rabies vaccine (PVRV-NG2) was developed using the same Pitman–Moore strain as in the licensed purified Vero cell vaccine (PVRV; Verorab) and the human diploid cell vaccine (HDCV; Imovax Rabies®).

Methods

This dual-center, modified, double-blind, phase 3 study evaluated the immunogenic non-inferiority and safety of PVRV-NG2 with and without concomitant intramuscular human rabies immunoglobulin (HRIG) versus PVRV + HRIG and HDCV + HRIG in a simulated post-exposure prophylaxis (PEP) regimen. Healthy adults ≥18 years old (N = 640) were randomized 3:1:1:1 to PVRV-NG2 + HRIG, PVRV + HRIG, HDCV + HRIG, or PVRV-NG2 alone (administered as single vaccine injections on days [D] 0, D3, D7, D14, and 28, with HRIG on D0 in applicable groups). Rabies virus neutralizing antibodies (RVNA) titers were assessed pre- (D0) and post-vaccination (D14, D28, and D42) using the rapid fluorescent focus inhibition test. Non-inferiority, based on the proportion of participants achieving RVNA titers ≥0.5 IU/mL (primary objective), was demonstrated if the lower limit of the 95% CI of the difference in proportions between PVRV-NG2 + HRIG and PVRV + HRIG/HDCV + HRIG was >−5% at D28. Safety was assessed up to 6 months after the last injection.

Results

Non-inferiority of PVRV-NG2 + HRIG compared with PVRV + HRIG and HDCV + HRIG was demonstrated. Nearly all participants (99.6%, PVRV-NG2 + HRIG; 100%, PVRV + HRIG; 98.7%, HDCV + HRIG; 100%, PVRV-NG2 alone) achieved RVNA titers ≥0.5 IU/mL at D28. Geometric mean titers were similar between groups with concomitant HRIG administration at all time points. Safety profiles were similar between PVRV-NG2 and comparator vaccines.

Conclusions

In a simulated PEP setting, PVRV-NG2 + HRIG showed comparable immunogenicity and safety to current standard-of-care vaccines. Clinical Trials Registration NCT03965962.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rabies VaccinesRabiesPost-Exposure ProphylaxisAntibodies, ViralAntibodies, NeutralizingRabies virusHumansAdultMaleFemaleDouble-Blind MethodMiddle AgedYoung AdultVero CellsFranceAnimalsChlorocebus aethiopsAdolescentImmunogenicity, VaccineHealthy Volunteers

Stichwörter der Autor:innen

PVRV-NG2immunogenicitypost-exposure prophylaxisrabiessafety

Substanzen

Rabies VaccinesAntibodies, ViralAntibodies, Neutralizing

Autor:innen und Institutionen

  • Global Clinical Immunology, Sanofi, Campus Mérieux, Marcy l'Etoile, France.
  • Patient Safety & Pharmacovigilance, Sanofi, Campus Carteret, Lyon, France.
  • Eurofins, Optimed, Gieres, France.
  • Biotrial, Rennes, France.

Förderung

  • Sanofi

Zitieren

APA

Pineda-Peña, A. C., Jiang, Q., Petit, C., Korejwo-Peyramond, J., Donazzolo, Y., Latreille, M., Homery, M. C., Babin, V., Benamor, S., Pichon, S., Guinet-Morlot, F., & Minutello, A. M. (2024). Immunogenicity and Safety of a Purified Vero Rabies Vaccine—Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial. Clinical Infectious Diseases, 78(6), 1748-1756. https://doi.org/10.1093/cid/ciae137

Vancouver

Pineda-Peña AC, Jiang Q, Petit C, Korejwo-Peyramond J, Donazzolo Y, Latreille M, et al. Immunogenicity and Safety of a Purified Vero Rabies Vaccine—Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial. Clinical Infectious Diseases. 2024;78(6):1748-1756. doi:10.1093/cid/ciae137

BibTeX
@article{PinedaPea2024,
  author = {Pineda-Peña, Andrea-Clemencia and Jiang, Qian and Petit, Celine and Korejwo-Peyramond, Joanna and Donazzolo, Yves and Latreille, Mathilde and Homery, Marie-Claude and Babin, Valerie and Benamor, Sonia and Pichon, Sylvie and Guinet-Morlot, Françoise and Minutello, Ada-Maria},
  title = {Immunogenicity and Safety of a Purified Vero Rabies Vaccine—Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {78},
  number = {6},
  pages = {1748--1756},
  doi = {10.1093/cid/ciae137}
}
Kostenlos starten →